MAP
CAPR icon

Moody Aldrich Partners’s Capricor Therapeutics CAPR Stock Holding History

Moody Aldrich Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.28M Sell
177,754
-48,274
-21% -$1.46M 0.77% 58
2026
Q1 		$6.87M Buy
226,028
+17,273
+8% +$460K 1.24% 12
2025
Q4 		$6.02M Buy
+208,755
New +$2.73M 1.12% 21

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Moody Aldrich Partners's CAPR Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Capricor Therapeutics (CAPR) stake by 21% in Q2 2026, selling an estimated $1.46M and leaving 177,754 shares worth $4.28M. The position accounts for 0.77% of the portfolio, ranked #58.

Moody Aldrich Partners first reported a position in CAPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.87M in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Moody Aldrich Partners held 177,754 shares of Capricor Therapeutics worth $4.28M as of Q2 2026.
  • Moody Aldrich Partners sold 48,274 Capricor Therapeutics shares in Q2 2026, an estimated $1.46M.
  • Capricor Therapeutics made up 0.77% of Moody Aldrich Partners's portfolio in Q2 2026, its #58 holding.
  • Moody Aldrich Partners first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Moody Aldrich Partners's Capricor Therapeutics position peaked at $6.87M in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.